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Abstract: Cardiovascular (CV) disease is a major factor in mortality rates around the world and 
contributes to more than one-third of deaths in the US. The underlying cause of CV disease is 
atherosclerosis, a chronic inflammatory process that is clinically manifested as coronary artery 
disease, carotid artery disease, or peripheral artery disease. It has been predicted that athero-
sclerosis will be the primary cause of death in the world by 2020. Consequently, developing 
a treatment regimen that can slow or even reverse the atherosclerotic process is imperative. 
Atherogenesis is initiated by endothelial injury due to oxidative stress associated with CV risk 
factors including diabetes mellitus, hypertension, cigarette smoking, dyslipidemia, obesity, 
and metabolic syndrome. Since the renin–angiotensin–aldosterone system (RAAS) plays a 
key role in vascular inflammatory responses, hypertension treatment with RAAS-blocking 
agents (angiotensin-converting enzyme inhibitors [ACEIs] and angiotensin II receptor blockers 
[ARBs]) may slow inflammatory processes and disease progression. Reduced nitric oxide (NO) 
bioavailability has an important role in the process of endothelial dysfunction and hypertension. 
Therefore, agents that increase NO and decrease oxidative stress, such as ARBs and ACEIs, may 
interfere with atherosclerosis. Studies show that angiotensin II type 1 receptor antagonism with 
an ARB improves endothelial function and reduces atherogenesis. In patients with hypertension, 
the ARB olmesartan medoxomil provides effective blood pressure lowering, with inflammatory 
marker studies demonstrating significant RAAS suppression. Several prospective, randomized 
studies show vascular benefits with olmesartan medoxomil: reduced progression of coronary 
atherosclerosis in patients with stable angina pectoris (OLIVUS); decreased vascular inflamma-
tory markers in patients with hypertension and micro- (pre-clinical) inflammation (EUTOPIA); 
improved common carotid intima-media thickness and plaque volume in patients with diagnosed 
atherosclerosis (MORE); and resistance vessel remodeling in patients with stage 1 hypertension 
(VIOS). Although CV outcomes were not assessed in these studies, the observed benefits in 
surrogate endpoints of disease suggest that RAAS suppression with olmesartan medoxomil may 
potentially have beneficial effects on CV outcomes in these patient populations.
Keywords: angiotensin II receptor blocker, antihypertensive, atherosclerotic process, cardio-
vascular outcomes, coronary artery disease, olmesartan medoxomil, RAAS suppression
Introduction
More than 83 million adults in the US (over one-third) have cardiovascular disease 
(CVD).1 In 2007, mortality data showed CVD to be the underlying cause of death in 
33.6% of all deaths in the US.1 Atherosclerosis, a progressive chronic inflammatory 
condition occurring in the walls of arteries,2 is the leading cause of CVD in the devel-
oped world, and atherosclerosis is predicted to be the primary cause of death worldwide 
by 2020.3 It is difficult to assess the exact frequency and prevalence of atherosclerosis. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Typically, it is an asymptomatic condition that can begin 
as early as childhood, whereas symptomatic organ-specific 
clinical manifestations often do not appear until 40 years of 
age or older when it is most commonly diagnosed.4
Atherosclerosis is characterized by the formation of 
arterial lesions or plaques as a result of an inflammatory 
response to endothelial injury.5 The plaque primarily com-
prises macrophages, lipid-dense macrophages (foam cells), 
low-density lipoproteins, and neutral lipids, with subsequent 
calcification and ulceration appearing around the outer base 
of more mature plaques.6,7 Atherosclerosis eventually leads to 
artery enlargement, arterial stenosis (resulting in insufficient 
blood supply to the associated organ), and may ultimately 
produce an arterial rupture.7
Atherosclerosis can develop in any artery and, depending 
on the specific artery affected, can potentially develop into 
three main types of disease – coronary, carotid, or peripheral 
artery disease (PAD).8 In coronary artery disease (CAD), 
formation of an atherosclerotic plaque in a coronary artery 
may result in a myocardial infarction, whereas in carotid 
artery disease, formation of a plaque may lead to a stroke.8 
Plaque formation in the arteries of the legs, arms, and/or 
pelvis leads to PAD, characterized by numbness, pain, and 
increased risk of infection and necrosis in the affected limb 
or region.8
Endothelial dysfunction is observed in the early stages 
of the atherogenic process, and it is initiated by injury to 
the arterial endothelium. Such injury has been associated 
with cardiovascular (CV) risk factors including diabetes 
mellitus or impaired glucose metabolism, hypertension, 
cigarette smoking, dyslipidemia, obesity, and/or metabolic 
syndrome.9
Hypertension is an established risk factor for the devel-
opment of atherosclerosis.10 Evidence suggests that hyper-
tension both promotes and accelerates the atherosclerotic 
process via inflammatory mechanisms linked to activation 
of oxidative stress by angiotensin II (Ang II), which subse-
quently leads to endothelial dysfunction and development of 
atherogenic lesions and plaque.5
The purpose of this literature-based review is to present 
a current understanding of the mechanisms of the atheroscle-
rotic process, including the roles of the renin–angiotensin– 
aldosterone system (RAAS) and nitric oxide (NO). In 
addition, a summary of the efficacy of several antihypertensive 
drug classes in improving CV outcomes, endothelial function, 
and reducing the progression of atherosclerosis is presented. 
Finally, recent clinical trial data for the angiotensin II receptor 
blocker (ARB) olmesartan medoxomil, which focuses on the 
utility of RAAS suppression in reducing atherosclerosis and/
or improving endothelial function, is discussed.
Mechanism of plaque formation  
in atherosclerosis
The endothelium is responsible for the release and regula-
tion of numerous vasoactive factors. In a disease-free state, 
the endothelium maintains these factors in homeostasis, 
resulting in normal control of vascular tone and function, as 
well as protecting against pro-atherogenic processes such 
as oxidation, monocyte adhesion, and the accumulation of 
lipids.11–13 However, initial injury to the endothelium, result-
ing from any of the abovementioned CV risk factors, alters 
the endothelial cell surface so that it becomes increasingly 
permeable and adhesive over time. Consequently, normal 
endothelial function becomes compromised and a series of 
cellular events are initiated, which ultimately results in the 
development of an atherosclerotic plaque.11
The increased permeability of arterial endothelial cells 
allows migration of low-density lipoprotein cholesterol 
(LDL-C) into the intima where it undergoes free radical 
oxidation. The presence of oxidized LDL-C then initiates an 
inflammatory response that includes the increased expres-
sion of circulating adhesion molecules including vascular 
cell adhesion molecule-1 (VCAM-1), intercellular adhe-
sion molecule-1 (ICAM-1), endothelial-leukocyte adhesion 
molecule-1 (E-selectin), and P-selectin.14 The presence of 
adhesion molecules and subsequent release of chemokines 
by macrophages, vascular smooth muscle cells (VSMCs), 
and endothelial cells results in the migration of peripheral 
leukocytes to the vascular wall.
Monocytes adhere to the endothelium via the interaction 
of adhesion molecules and infiltrate into the intima where 
they differentiate into macrophages, which is facilitated by 
proteins such as macrophage colony-stimulating factor.11 
These macrophages then proceed to ingest the oxidized 
lipids via their scavenger receptors, thereby accumulating 
LDL-derived cholesterol esters. This process results in the 
formation of lipid-dense macrophage foam cells.11 Interac-
tions between foam cells and T-helper 1 and 2 (Th1 and 
Th2) cells cause the release of various inflammatory mol-
ecules and cytokines, including interferon-gamma (IFN-γ), 
CD40 ligand, and interleukins (IL).15 Tumor necrosis factor 
(TNF)-α, IFN-γ, and other cytokines then activate vascular 
endothelial cells, macrophages, and VSMCs.15 VSMCs 
proliferate and migrate from the media to the intima and 
accumulate along with the macrophages. Once there, inter-
actions between T-helper cells, macrophages, and VSMCs Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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stimulate secretion of additional inflammatory mediators, 
resulting in a chronic inflammatory response.
Advanced atherosclerotic lesions have a lipid-rich 
necrotic core due to the death of macrophages and VSMCs, 
and the continued release of lipids and other cellular com-
ponents.16 Subsequent deposition of an interstitial fibrous 
matrix, composed of fibrin, collagen, and proteoglycans, 
results in the formation of a fibrous cap enclosing and stabi-
lizing the underlying plaque.17
Outcomes and potential consequences  
of plaque formation
Following formation of a stable plaque, plaque destabiliza-
tion can occur in the presence of one or more CV risk factors, 
particularly dyslipidemia. The vulnerable plaque can then 
rupture, resulting in platelet aggregation and thrombosis.6,16 
The mechanisms of plaque destabilization are complex.18 
Initially, macrophages release proinflammatory cytokines 
that precipitate changes in the plaque surface and create a 
prothrombotic state.19 Levels of protein-S and tissue plas-
minogen are reduced, and the release of metalloproteinases 
from macrophages and T cells, together with a reduction in 
collagen synthesis by VSMCs, results in degradation of the 
plaque’s elastin and collagen fibrous cap.20 Simultaneous 
neovascularization occurs, resulting in further destabilization 
of the plaque and, ultimately, rupture.6 The main determi-
nants of plaque vulnerability and rupture are related to their 
composition rather than size, and include lipid content and 
macrophage-related inflammation, as well as impaired heal-
ing and repair mechanisms.16
Following rupture, activation of the coagulation cas-
cade, fibrin deposition, and platelet activation lead to 
the formation of a localized thrombus, which can cause 
obstruction of blood flow in the affected artery (arterial 
occlusion) and tissue ischemia.19 Plaque rupture can be 
fatal. If the plaque ruptures suddenly and is in a coronary 
artery, this can result in acute coronary syndrome (unstable 
angina, acute myocardial infarction, and/or sudden death).21 
Alternatively, plaque rupture in a carotid artery leads to 
symptomatic carotid artery disease and increased risk of 
ischemic stroke.4
The endothelium possesses an endogenous regenera-
tive capacity mediated primarily by bone marrow-derived 
endothelial progenitor cells. This repair process is ongoing 
and takes place after endothelial injury, both during plaque 
formation and after plaque rupture. However, the ability to 
undertake such repair and regeneration of damaged endothe-
lium is adversely affected by CV risk factors, as shown by 
a marked reduction in the level of endothelial progenitor 
cells in high-risk patients.22
Role of the renin–angiotensin–
aldosterone system in inflammation 
and atherosclerosis
In the nonpathological state, hemodynamic stability is pre-
served by the RAAS via the regulation of fluid balance and 
sodium levels, as well as direct and indirect vascular effects.15 
However, excessive RAAS activity is associated with 
atherogenesis via its role in the initiation and maintenance 
of the vascular inflammatory response, and is implicated in 
the development of atherosclerosis and vascular events.15 
Binding of Ang II, the major effector peptide of the RAAS, 
to the angiotensin II type 1 (AT1) receptor produces a range 
of effects including vasoconstriction and both sodium and 
fluid retention. In addition, Ang II mediates both mitogenic 
and proliferative effects on vascular endothelial and smooth 
muscle cells.23
There is substantial evidence supporting the hypothesis 
that Ang II plays a significant role in the initiation and pro-
gression of atherogenesis.24 For example, the recruitment of 
inflammatory cells to injured arteries by Ang II is one of the 
initial events in atherogenesis. Inflammatory cells at the site 
of injury then subsequently produce Ang II, resulting in a 
positive feedback loop that perpetuates a proinflammatory 
cycle.15 In addition, Ang II-related mechanisms have been 
implicated in arterial fibrosis,25 endothelial dysfunction,26 
oxidative stress,24 and plaque instability.27
Role of nitric oxide  
in atherosclerosis
The endothelium is also responsible for the release and 
regulation of numerous vasoactive substances, including 
NO. NO mediates the relaxation and vasodilation of VSMCs; 
prevents leukocyte adhesion and migration into the arterial 
wall; inhibits platelet activation, adhesion, and aggregation; 
and inhibits VSMC proliferation.9,29
Impaired NO bioavailability has been shown to play an 
important role in the process of endothelial dysfunction9 and 
subsequent atherogenesis.29 Oxidative stress generated by 
CV risk factors is a major cause of NO inactivity,30 creating 
an imbalance that results in increased levels of superoxide 
anions (O2
–). All CV risk factors increase levels of reactive 
oxygen species (ROS; or oxygen-derived free radicals). For 
example, in patients with hypertension, the main source of 
oxygen-derived free radicals is the cyclooxygenase (pros-
tanoid) pathway.31,32 Subsequent increased reactions between Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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NO and superoxide anions create the highly reactive oxidant 
peroxynitrite (ONOO–).33 Loss of NO bioavailability is 
associated with enhanced levels of endothelin-1 and Ang II. 
These factors contribute to reduced vasodilation, increased 
adhesion of platelets and leukocytes at the site of endothelial 
injury, VSMC migration and proliferation, and deposition of 
lipids into the intima.12,13,29,34
Endothelial dysfunction itself has been shown to be 
directly associated with hypertension, and is thought to con-
tribute to functional abnormalities in resistance vessels (eg, 
impaired endothelial-dependent vasodilation) observed in 
patients with hypertension.35,36 Not only is free radical-related 
reduction in NO bioavailability a major cause of endothelial 
dysfunction in patients with hypertension, but it is thought that 
oxidative stress could be a common mechanism of endothelial 
dysfunction associated with other CV risk factors.31
Restoration of vascular function with 
antihypertensive agents: clinical data 
and mechanism of action studies
Antihypertensive agents that increase NO, decrease oxi-
dative stress, and/or reduce RAAS-associated inflammation 
have been shown to slow the progression of the atherogenic 
process.37,38
ARBs and angiotensin-converting enzyme inhibitors 
(ACEIs) are agents that directly affect the RAAS, either by 
blocking the binding of Ang II to the AT1 receptor or decreas-
ing the production of Ang II, respectively, and therefore may 
be beneficial in treating patients with atherosclerosis.37 These 
RAAS antagonists, as well as some dihydropyridine calcium 
channel blockers (CCBs), possess ancillary and synergistic 
effects that increase NO bioavailability, reduce oxidative 
stress, and suppress inflammatory responses, thereby improv-
ing both endothelial activity and vascular function.39
ACeis and CCBs: effect on CV outcomes 
in high-risk patients
Several large, long-term clinical studies have investigated 
the effect of ACEIs and CCBs on CV outcomes in high-risk 
patients.36 The HOPE (Heart Outcomes Prevention Evalu-
ation) study was a 2 × 2 factorial trial undertaken in 9297 
patients aged $ 55 years at high risk of adverse CV outcomes 
(existing vascular disease or diabetes plus one other CV risk 
factor, but no reduction in ejection fraction or heart failure 
was required). HOPE compared the ACEI ramipril 10 mg 
once daily vs placebo over 5 years for effect on the primary 
study outcome – composite of myocardial infarction, stroke, or 
death from CV causes.40 The HOPE findings demonstrated that 
ramipril significantly improved the rate of the primary compos-
ite endpoint vs placebo (14.0% vs 17.8%; P , 0.001). Ramipril 
also improved rates of individual endpoints significantly more 
than placebo (all P # 0.005). These effects were thought to 
be mainly independent of blood pressure (BP) reduction since 
the majority of patients did not have hypertension at baseline, 
and the mean BP reduction was very low.40
The effect of amlodipine on the progression of athero-
sclerosis and the occurrence of clinical CV events was deter-
mined in 825 patients with angiographically documented 
CAD in the PREVENT (Prospective Randomized Evalu-
ation of the Vascular Effects of Norvasc Trial) study.41 In 
PREVENT, amlodipine significantly slowed the 36-month 
progression of atherosclerosis in carotid arteries as assessed 
by B-mode ultrasonography; intima-media thickness (IMT) 
decreased by 0.0126 mm in the amlodipine-treated patients 
compared with an increase of 0.033 mm in the placebo group 
(P = 0.007 vs placebo).41
The CAMELOT (Comparison of Amlodipine vs Enalapril 
to Limit Occurrences of Thrombosis) study showed that in 
patients with normal BP (mean baseline BP = 129/78 mmHg) 
and documented CAD, amlodipine therapy resulted in 
a significant reduction in adverse CV events vs placebo 
(P = 0.003), and a trend toward reduced progression of 
atherosclerosis vs placebo (P = 0.12). In a subgroup of 
patients with baseline systolic BP greater than the mean, the 
rate of atherosclerosis progression was significantly lower 
with amlodipine compared with placebo (P = 0.02). A trend 
towards a correlation between BP reduction and progression 
of atherosclerosis was observed (P = 0.07).42
SECURE (Study to Evaluate Carotid Ultrasound Changes 
in Patients Treated With Ramipril and Vitamin E) was a 
randomized, double-blind substudy of the HOPE trial in 732 
patients aged $ 55 years with vascular disease or diabetes, 
and at least one other CV risk factor. In addition, patients 
could not have heart failure or a low left ventricular ejection 
fraction. SECURE demonstrated that the rate of progression 
of the mean maximum carotid artery IMT was significantly 
lower in the ramipril 10 mg once-daily treatment group vs 
placebo (P = 0.028) over an average follow-up period of 
4.5 years. The difference in mean IMT progression between 
ramipril and placebo remained significant (P , 0.05) 
after adjustment for BP changes and after multivariate 
adjustment.43
Mechanisms of action
The mechanisms of action behind the improvement in 
CV outcomes reported with ACEIs and CCBs are not Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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fully   understood. ACEIs are known to interfere with the 
  breakdown of bradykinin, which stimulates NO release.9 
ACEIs also inhibit the production of endothelin-1 and Ang 
II by the endothelium, which reduces the production of 
superoxide anion, further increasing the levels of available 
NO.44 Mechanistic studies have shown that in patients with 
hypertension, vessel wall elasticity is improved and arterial 
stiffness reduced by calcium channel or RAAS blockade,39 
as shown by a significant reduction in the central aortic 
augmentation index.45,46 Long-acting CCBs, eg, amlodipine, 
are also known to protect against oxidation of low-density 
lipoprotein (LDL) and membrane lipids via their antioxidant 
effects, which are independent of BP lowering.47
Mechanisms and clinical effect of ARBs on 
endothelial function and atherosclerosis
Figure 1 shows some of the known effects on the mechanisms 
of atherosclerosis resulting from the binding of Ang II to the 
AT1 receptor.48 Clinical trials have demonstrated that ARBs 
can improve endothelial function and/or reduce markers of 
atherosclerosis via AT1 receptor antagonism. Candesartan 
improves endothelial function as evidenced by significantly 
increasing flow-mediated dilation in patients with hyperten-
sion, stable CAD, and endothelial dysfunction.49 Candesartan 
significantly improves the percent flow-mediated dilator 
response to hyperemia (P = 0.019); significantly decreases 
plasma levels of plasminogen activator inhibitor type-1 
(PAI-1) antigen (P , 0.001) as well as monocyte chemoat-
tractant protein-1 (P = 0.004),50 and significantly reduces 
circulating levels of ICAM-1 and VCAM-1 (P , 0.05).51 
Candesartan has also been shown to slow the progression of 
carotid remodeling in patients with hypertension and type 
2 diabetes.52 Experimental in vitro and in vivo studies with 
candesartan suggest that a possible mechanism of action for 
the anti-inflammatory effect seen with ARBs may include 
the suppression of toll-like receptor (TLR) 2 and TLR4 
expression.53 TLR2 and TLR4 are thought to participate in 
the inflammatory process of atherosclerosis.2
Clinical studies have shown that in patients with hyperten-
sion, irbesartan significantly increases endothelium-dependent 
and endothelium-independent vasodilation while significantly 
decreasing plasma endothelin (P = 0.001) and restoring the 
vasoconstriction capacity of NOS inhibitors.54,55 Irbesartan has 
also been shown to reduce fibrinogen and thrombomodulin;56 
PAI-1;56,57 nitrotyrosine;58 C-reactive protein (CRP), ICAM-1, 
and IL-6;57,58 and plasma levels of 8-isoprostane (a marker 
of oxidative stress).57 In addition, clinical data demon-
strate that irbesartan significantly increases flow-mediated 
Platelet aggregation
Endothelial dysfunction
Angiotensin II
Tissue remodeling
Oxidative stress Inflammation
MMP activation
Matrix deposition
Proliferation of VSMCs
•
•
•
•
•
Production of inflammatory mediators
Adhesion molecules (VCAM-1, ICAM-1,
E-selectin, P-selectin, L-selectin,
B2-integrin...)
Chemokines (MCP-1, interleukin 8...)
Cytokines (interleukin 1 & 6, TNF-α,
IFN-y, TNF-β...)
Growth factors (TGF-β1...)
CRP
PAI-1 activation
Vasoconstriction
Nitric oxide ↓
LDL peroxidation, LOX-1 ↑
Reactive oxygen species ↑
NAD(P)H oxidase activity ↑ Vascular permeability ↑, leukocyte infiltration ↑
Activation of signaling pathways (NF-κB, TLR2, TLR4...)
Figure 1 effects of angiotensin ii on the mechanisms associated with the arthrosclerotic process.
Abbreviations: CRP, C-reactive protein; iCAM-1, intercellular adhesion molecule-1; iFN-γ, interferon-gamma; LDL, low-density lipoprotein; LOX-1, lectin-like oxidized 
LDL receptor; MCP-1, monocyte chemoattractant protein-1; MMP, matrix metalloproteinase; PAi-1, plasminogen activator inhibitor type-1; TGF-β1, transforming growth 
factor-beta-1; TNF, tumor necrosis factor; TLR, toll-like receptor; VSMCs, vascular smooth muscle cells; VCAM-1, vascular adhesion molecule-1.
Reprinted from Schmieder Re, et al. Renin-angiotensin system and cardiovascular risk. The Lancet. 2007;369:1208–1219. Copyright with permission from elsevier.48Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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vasodilation.57,58 Overall, blockade of the RAAS by irbesartan 
has been shown to improve endothelial function beyond that 
expected by BP lowering alone.59
In patients with hypertension, losartan has been shown 
to prevent the production of connective tissue growth fac-
tor and transforming growth factor-β (known mediators of 
Ang II-induced remodeling of resistance arteries) as well 
as improve the media:lumen ratio in resistance arteries.60 
Furthermore, clinical trial data demonstrate that losartan 
can attenuate the oxidation of LDL (P = 0.001) in patients 
with type 2 diabetes,61 significantly reduce 8-isoprostane 
(P = 0.01),62 and significantly decrease common carotid 
artery IMT (P , 0.05).63
Several valsartan studies have demonstrated RAAS sup-
pression and an associated reduction in inflammation. Valsartan 
has been shown to significantly suppress the generation of ROS 
in polymorphonuclear and mononuclear cells of normal sub-
jects (P , 0.01). It has also been shown to suppress the activity 
of NF-kB binding activity (P , 0.01), which is responsible 
for regulating the transcription of genes for proinflammatory 
cytokines, adhesion molecules, chemokines, and protein 
subunits of ROS-generating enzymes. Valsartan significantly 
increased the expression of inhibitor kB (P , 0.05), which 
binds to NF-kB and prevents it from translocating into the 
nucleus, thus preventing transcription of proinflammatory 
genes, and has also been shown to significantly decrease 
plasma CRP concentration (P , 0.01).64 Furthermore, 
valsartan significantly reduced TNF-α (P = 0.006) and IL-6 
(P = 0.005) in patients with essential hypertension.65
The mechanism of the anti-inflammatory effects of telmis-
artan was investigated in a 12-week, double-blind, placebo-con-
trolled study in patients with hypertension and CAD. A range 
of inflammatory markers were assessed, ie, high-  sensitivity 
CRP (hsCRP), IL-6, and cell adhesion molecules, soluble 
ICAM-1, leukocyte adhesion molecule soluble-L-selectin, and 
the β2 integrin Mac-1; however, only Mac-1 expression was 
significantly decreased by telmisartan.66 Associated in vitro 
studies conducted to elucidate the mode of action showed that 
telmisartan dose-dependently inhibited β2-integrin expression 
in lymphocytes in either the absence or presence of Ang II, 
suggesting that the atheroprotective effects associated with 
telmisartan are independent of the AT1 receptor.66
Studies investigating the anti-atherogenic 
mechanism of action of olmesartan 
medoxomil
The ARB olmesartan medoxomil has demonstrated effective 
BP lowering in numerous clinical trials with a tolerability 
profile similar to that of placebo.67 Moreover, olmesartan 
  medoxomil has been shown to be efficacious across a wide 
range of patient subgroups.68,69 In vitro and in vivo animal 
studies have suggested anti-atherogenic and anti-inflamma-
tory effects of olmesartan medoxomil. In an in vitro study 
investigating the effect of olmesartan on Ang II-induced 
migration of VSMCs from the rat aorta, data showed olm-
esartan to be a potent inhibitor of VSMC migration, with 
the inhibitory effect being mediated via Src- and mitogen-
activated protein kinase pathways.70
These findings suggest that olmesartan medoxomil may 
potentially prevent vascular remodeling associated with 
VSMC migration. In addition, animal studies have demon-
strated the effects of olmesartan on the suppression or regres-
sion of fatty streak plaque,71,72 and reduction of superoxide 
generation and overload of oxidative stress on the aortic 
walls.71 In vitro experiments have shown that olmesartan 
also suppressed levels of IFN-γ, macrophage inflammatory 
protein-2, and thioredoxin (a marker of oxidative stress) in 
cultured cells.71
Clinical effect of olmesartan medoxomil  
on endothelial function  
and atherosclerosis
Study data from several recent olmesartan medoxomil clinical 
trials demonstrate the utility of RAAS suppression in reduc-
ing atherosclerosis and/or improving endothelial function.73–76 
These studies are summarized in Table 1.
OLiVUS
The most recent of these trials was the OLIVUS (Impact of 
Olmesartan on Progression of Coronary Atherosclerosis: 
Evaluation by Intravascular Ultrasound) study, which was a 
prospective, randomized trial designed to assess the effect 
of olmesartan medoxomil on the progression of coronary 
atherosclerosis.73 More specifically, this study evaluated the 
effect of olmesartan medoxomil on coronary atherosclerotic 
changes assessed by volumetric intravascular ultrasound 
(IVUS) in 247 patients with stable angina pectoris with native 
CAD. Patients were randomly assigned to receive olmesar-
tan medoxomil 10, 20, or 40 mg or control (placebo), and 
also received a combination of β-blockers, CCBs, diuretics, 
nitrates, glycemic control agents, and/or statins, according to 
their physician’s guidance (Table 1). Serial IVUS examina-
tions were performed at baseline and at 14 months to assess 
coronary atheroma volume. IVUS was performed in noncul-
prit vessels (without angiographically documented coronary 
stenosis; ,50%) when patients underwent percutaneous Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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coronary intervention for culprit lesions.73 Volumetric IVUS 
analyses included lumen, plaque, and vessel volume; percent 
atheroma volume (PAV); and total atheroma volume (TAV). 
After 14 months of active therapy, IVUS showed a significant 
decrease in TAV and a significant percentage improvement in 
PAV in olmesartan medoxomil recipients: 5.4% vs 0.6% for 
TAV and 3.1% vs –0.7% for PAV , for placebo vs olmesartan 
medoxomil, respectively (P , 0.05 for all vs placebo; Table 1 
and Figure 2).73 BP control was identical between olmesartan 
medoxomil and placebo (control) groups.   OLIVUS dem-
onstrated that olmesartan medoxomil decreased the rate of 
coronary atheroma progression in patients with stable angina 
pectoris, independent of BP lowering.
eUTOPiA
The EUTOPIA (European Trial on Olmesartan and Prava-
statin in Inflammation and Atherosclerosis) study was a 
prospective, double-blind, multicenter trial evaluating the 
anti-inflammatory effects of olmesartan medoxomil, with or 
without pravastatin, in 211 patients with hypertension and 
microinflammation.76 Patients were randomized to olmesar-
tan medoxomil or placebo for 12 weeks, with pravastatin 
added to both treatment arms at week 6, and hydrochloro-
thiazide (HCTZ) added as necessary to control BP (Table 1). 
A panel of vascular inflammation markers was assessed at 
baseline, 6 weeks (primary endpoint), and 12 weeks. At 
6 weeks, olmesartan medoxomil significantly reduced the 
levels of hsCRP, high-sensitivity TNF-α (hsTNF-α), IL-6, 
and monocyte chemotactic protein, whereas placebo had 
no effect (Table 1 and Figure 3). After 12 weeks, hsCRP, 
hsTNF-α, and IL-6 were further decreased in the olmesartan 
medoxomil plus pravastatin arm, but no significant reduction 
in anti-inflammatory markers was observed with pravastatin 
alone from weeks 6 to 12. Pravastatin monotherapy sig-
nificantly reduced LDL-C in both arms.76 In the EUTOPIA 
study, Ang II receptor blockade with olmesartan medoxomil 
Table 1 Olmesartan medoxomil (OM) studies investigating the utility of renin–angiotensin–aldosterone system suppression in reducing 
atherosclerosis and/or improving endothelial function
Study  
name
Design  
(duration)
Interventions Patients (n) Endpoints Results
OLiVUS73 P, R  
(14 mo)
OM 10, 20, or 40 mg/d  
PLA  
(+β-blockers, CCBs,  
diuretics, nitrates,  
antiglycemics,  
and/or statins prn)
Stable angina with  
native CAD (247)
Vascular morphology:
lumen, plaque, vessel  
volume, PAV, and TAV  
assessed by iVUS in  
nonculprit vessels  
during PCi
Significantly greater  
improvement in TAV  
and PAV with OM vs PLA  
(P , 0.05)
eUTOPiA76 P, DB, R  
(12 wk)
OM  
PLA  
(+HCTZ 12.5 or  
25 mg/d prn  
and pravastatin 20 mg  
od at wk 6)
HTN and  
microinflammation (211)
Inflammatory markers
Primary: hsCRP, hsTNF-α,  
iL-6, iCAM-1, and  
MCP at 6 wk
Secondary: markers  
at 12 wk
Significant reduction in hsCRP,  
hsTNF-α, and iL-6 with OM +  
pravastatin from 6 wk
No changes in markers with  
pravastatin alone
MORe74 P, R (2 yr) OM 20–40 mg/d  
ATe 50–100 mg/d
HTN, high CV risk,  
elevated carotid iMT,  
and atherosclerotic  
plaque (165)
Common carotid artery  
iMT and PV assessed by  
noninvasive ultrasound
OM and ATe produced similar  
changes in iMT and PV at 2 yr
Significantly greater PV  
regression with OM in patients   
with baseline PV $ 33.7 μL  
(P = 0.023 vs ATe)
ViOS77 P, R (1 yr) OM 20–40 mg/d  
ATe 50–100 mg/d  
(treat to goal + HCTZ,  
amlodipine, or  
hydralazine prn)
Stage 1 HTN (49)  
Normal controls (11)
Change in percentage  
wall:lumen ratio of  
small resistance vessels  
assessed by pressurized  
myography
1-year change in wall: 
lumen ratio
Significantly reduced with  
OM (14.9%–11.1%; P , 0.01)
No significant change from  
baseline with ATe (P = NS)
Controls: 11.0%
Abbreviations:  ATe,  atenolol;  CAD,  coronary  artery  disease;  CCBs,  calcium  channel  blockers;  CRP,  C-reactive  protein;  CV,  cardiovascular;  DB,  double-blind;   
EUTOPIA, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis; HCTZ, hydrochlorothiazide; hs, high sensitivity; HTN, hypertension; 
iCAM-1, intracellular adhesion molecule-1; iL, interleukin; iMT, intima-media thickness; iVUS, intravascular ultrasound; MCP, monocyte chemotactic protein; mo, month(s); 
MORE, Multicenter Olmesartan Atherosclerosis Regression Evaluation; NS, not significant; od, once daily; OLIVUS, Impact of Olmesartan on Progression of Coronary 
Atherosclerosis: evaluation by intravascular Ultrasound; P, prospective; PAV, percent atheroma volume; PLA, placebo; PCi, percutaneous coronary intervention; prn, as 
needed; PV, plaque volume; R, randomized; TAV, total atheroma volume; TNF, tumor necrosis factor; ViOS, Vascular improvement with Olmesartan Medoxomil Study; wk, 
week(s); yr, year(s).Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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and plaque volume after 2 years of therapy in 165 patients 
with atherosclerosis. Patients received olmesartan medoxomil 
20–40 mg/day or atenolol 50–100 mg/day for 2 years. Two- 
and three-dimensional ultrasound was used to determine the 
change from baseline in common carotid IMT and plaque 
volume, respectively, after 28, 52, and 104 weeks of therapy 
(Table 1).74
Olmesartan medoxomil and atenolol both resulted in simi-
lar and significant reductions in carotid IMT. There were no 
between-treatment differences in plaque volume. In a post hoc 
analysis in patients with a baseline plaque volume $ median 
(33.7 μL), plaque volume significantly regressed with olm-
esartan medoxomil but not with atenolol, even though BP 
reductions were comparable (Table 1 and Figure 4).74 Com-
mon carotid IMT and BP decreased similarly with olmesartan 
medoxomil and atenolol. In addition, there was a preferential 
reduction in the volume of larger atherosclerotic plaques with 
olmesartan medoxomil compared with atenolol.
ViOS
The VIOS (Vascular Improvement With Olmesartan Medox-
omil Study) study investigated the impact of RAAS sup-
pression by AT1 receptor blockade on small resistance vessel 
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Reprinted with permission from Fliser D, et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. 
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Figure 2 OLiVUS study: change in intravascular ultrasound (iVUS) parameters from 
baseline to 14-month follow-up. An olmesartan medoxomil (OM)-based treatment 
regimen significantly decreased total atheroma volume (TAV) and percent change 
in percent atheroma volume (PAV) as demonstrated by iVUS in patients with stable 
angina pectoris and native coronary artery disease.
significantly reduced vascular inflammation/inflammatory 
markers in patients with hypertension.
MORe
The MORE (Multicenter Olmesartan Atherosclerosis Regres-
sion Evaluation) study compared the effect of olmesartan 
medoxomil vs atenolol on changes in common carotid IMT Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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remodeling – an effect thought to provide more complete 
end-organ protection than BP lowering alone.75 Patients with 
stage 1 hypertension were randomized to olmesartan medox-
omil 20–40 mg/day or atenolol 50–100 mg/day plus HCTZ, 
amlodipine, or hydralazine, as needed, to achieve a BP goal 
of ,140/90 mmHg (Table 1). Subcutaneous gluteal resistance 
arteries were examined on a pressurized myograph to evaluate 
remodeling at baseline and after 1 year of active treatment.75
Data from VIOS showed that the wall:lumen ratio in 
arteries obtained from olmesartan medoxomil recipients 
was significantly reduced (P , 0.01) after 1 year of active 
therapy, whereas no significant change was seen in patients 
receiving atenolol (Table 1 and Figure 5).77 BP was reduced 
to a similar level by both agents. VIOS showed that AT1 
receptor blockade with olmesartan medoxomil reduced the 
wall:lumen ratio in resistance arteries in patients with hyper-
tension, independently of BP reduction, and resulted in ratios 
similar to normotensive controls after 1 year of treatment.77 
In addition, the augmentation index, a surrogate measure for 
vascular compliance, was significantly (P , 0.05) reduced 
from baseline with the olmesartan medoxomil-based regi-
men but not with the atenolol-based regimen. This result 
provided noninvasive evidence that olmesartan medoxomil 
improved vascular compliance in association with the afore-
mentioned improvement in resistance vessel morphology.
Summary
Atherosclerosis is a complex disease that is associated with 
CV events including myocardial infarction, unstable angina, 
and sudden cardiac death, as well as cerebrovascular events 
and peripheral thromboses. Endothelial dysfunction is a hall-
mark early event in atherogenesis. Endothelial cells produce a 
number of vasoactive substances responsible for maintaining 
vascular tone. Local impairment of the endothelium associ-
ated with CV risk factors creates an imbalance between the 
normal concentrations of vasodilating and vasoconstricting 
factors, in particular, an increase in Ang II and a decrease in 
NO. Impaired NO bioavailability as a consequence of oxida-
tive stress and increased levels of Ang II results in increased 
vasoconstriction, and both of these processes play key roles 
in endothelial dysfunction and atherosclerosis. The RAAS, 
and its primary mediator Ang II, also have a direct influence 
on the progression of the atherosclerotic process via effects 
on endothelial function, inflammation, fibrinolytic balance, 
and plaque stability.
Agents in the ARB, ACEI, and CCB drug classes have 
demonstrated beneficial effects on the atherosclerotic 
  process. The clinical trial data presented in this review for the 
ARB olmesartan medoxomil demonstrate anti-atherogenic 
effects in a range of patient types, as well as provide evidence 
of slowing atheroma progression, reducing vascular inflam-
mation, decreasing carotid IMT and atherosclerotic plaque 
volume, and improving the arterial wall:lumen ratio. These 
data complement the results from several animal model and 
in vitro studies, which serve to elucidate the mechanisms 
of the anti-atherogenic effect. The aforementioned clinical 
changes observed in the olmesartan medoxomil studies may 
have a beneficial effect on improving endothelial dysfunction 
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Figure 5 VIOS study: an olmesartan medoxomil regimen significantly reduced the 
wall:lumen ratio in arteries to values similar to those observed in normotensive 
controls at 1 year of therapy. Conversely, no significant change in wall:lumen ratio 
was observed in arteries from atenolol-treated patients.
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and, consequently, slowing atherogenesis. Although long-
term CV outcomes were not assessed in these studies, the 
observed changes provide a rationale for prospective trials 
to ascertain the role of olmesartan medoxomil in reducing 
the risk or severity of CVD.
Conclusion
Certain antihypertensive agents have been shown to effec-
tively slow the process of atherogenesis in clinical evalua-
tions. Both ARBs and ACEIs affect the RAAS directly, either 
by blocking the binding of Ang II to the AT1 receptor or by 
decreasing production of Ang II. These RAAS antagonists, 
as well as certain dihydropyridine CCBs, possess both ancil-
lary and synergistic effects that increase NO bioavailability, 
reduce oxidative stress, and/or suppress RAAS-associated 
inflammatory response, as shown by the effect of such 
agents on a range of inflammatory markers. These changes 
bring about an improvement in endothelial activity and 
vascular function, and may additionally be associated with 
benefits beyond BP lowering in the treatment of patients with   
atherosclerosis and hypertension.
Data from the olmesartan medoxomil clinical trials 
OLIVUS, EUTOPIA, VIOS, and MORE have demonstrated 
the specific utility of RAAS suppression in reducing athero-
sclerotic plaque volume, improving plaque composition and 
stability, and in improving endothelial dysfunction. These 
studies have shown that olmesartan medoxomil treatment 
may slow the progression of atherosclerosis, thereby poten-
tially improving CV outcomes.
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